Orbax

Quick links to important sections

Orbax

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orbax

Quick Facts: Orbax (Orbifloxacin)

Property Description
Active ingredient Orbifloxacin (C19H20F3N3O3)
Form Oral Tablets, Oral Suspension
Pharmacological class Fluoroquinolone Antibiotic
Target Group Dogs and Cats (veterinary medicine)
Origin Synthetic

What is Orbax? Definition and Pharmacological Class

Orbax is the commercial name for the drug containing orbifloxacin, a synthetic broad-spectrum antibacterial agent used exclusively in veterinary medicine for treating systemic infections in companion animals. Orbifloxacin is officially classified as a fluoroquinolone antibiotic. This classification confirms that the medicine belongs to a group of manufactured compounds used to eliminate a wide range of bacterial pathogens.

Its structure defines it as a quinolone carboxylic acid derivative, reflecting its origin as a manufactured chemical compound, which grants it consistent pharmacological properties. Its core purpose is to serve as an antimicrobial agent to stop the proliferation of harmful bacteria.

Composition, Origin, and Available Forms

Orbax contains orbifloxacin as the single active ingredient, confirming it is a single-entity product derived from a fully synthetic source. It is provided for oral administration in two distinctive dosage forms: Oral Tablets and an Oral Suspension. A key differentiating factor for the Oral Suspension is its formulation with a liquid vehicle that is often malt flavored. This feature addresses the practical challenges of administering medication to the targeted patient group, the animals, to support compliance in treatment.

How Orbifloxacin Acts: General Purpose

The action of orbifloxacin is fundamentally bactericidal, meaning its design is to directly and actively kill susceptible bacteria, rather than just slowing their growth. This mechanism involves disrupting the bacteria's critical genetic machinery. The overarching general purpose of this destructive mechanism is the systematic elimination of the bacterial population, which is essential for managing and resolving the underlying bacterial disease.

Regulatory References

  1. DailyMed, NIH

What side effects are possible with Orbax?

Possible Side Effects and Safety Information

Orbifloxacin (Orbax) is a fluoroquinolone antibiotic associated with specific safety warnings rooted in its drug class. Common side effects are generally mild and may include gastrointestinal upset such as vomiting, soft feces, or diarrhea. These effects are often transient.

Serious and Clinically Significant Adverse Reactions

The most critical safety concern is arthropathy (damage to joint cartilage) in immature, growing dogs. Due to this risk, the medication is strictly contraindicated in dogs during their rapid growth phase (which varies from 2–8 months in small breeds up to 18 months in large/giant breeds).

In cats, use requires caution due to reports of adverse effects on the retina and potential blindness, especially when high doses are administered. The maximum approved daily dose for cats must not be exceeded. In some cases, blindness has been temporary.

Rare, but serious, post-approval adverse events reported include neurologic effects (e.g., convulsive seizures, ataxia, CNS stimulation), hypersensitivity reactions (e.g., anaphylaxis, facial edema), lethargy, and depression.

Safety and Restriction Considerations

Population Key Safety Consideration/Restriction
Immature Dogs Contraindicated due to risk of articular cartilage erosion (arthropathy).
Cats Do not exceed 7.5 mg/kg per day due to ocular toxicity risk.
CNS Disorders Use with caution; rare association with CNS stimulation and seizures.
Hepatic Impairment Administer with caution in the presence of liver insufficiency.

Orbifloxacin is also contraindicated in animals with known hypersensitivity to quinolone antibiotics. Caution is advised regarding concurrent oral administration with substances containing divalent or trivalent cations (such as iron, aluminum, calcium, magnesium, or zinc, including some antacids or supplements), as these compounds may significantly interfere with the absorption and effectiveness of the medication.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Orbifloxacin (Orbax) overdose describes specific signs observed in high-dose safety studies and outlines mandated emergency procedures.


Documented Overdose Manifestations

Feature Official Regulatory Statement
Gastrointestinal Effects Vomiting, profuse salivation, soft, mucoid, or watery feces, and anorexia.
Neurological Effects Depression, lethargy, ataxia, and in severe cases, convulsions (seizures).
Ocular Toxicity Blindness (potential), retinal adverse effects, and tapetal hyperreflectivity.

Urgent Action Required

Official regulatory statements mandate specific actions in case of overdose or the appearance of severe signs:

  • Immediate Discontinuation: The medication must be discontinued immediately if a visual deficit is suspected, particularly in cats, due to the risk of irreversible ocular damage.
  • Seek Immediate Help: Contact the veterinarian immediately upon observing severe clinical signs such as convulsions or the onset of blindness.
  • Management: Treatment is limited to symptomatic treatment and observation, as no specific antidote is known or documented in official labeling.

Population-Specific Overdose Considerations

The feline species is uniquely susceptible to retinal adverse effects at high doses, and regulatory documents stress that the maximum recommended dose must not be exceeded in cats. In dogs, gastrointestinal signs are documented in studies at dose levels exceeding 22.5 mg/kg.

Therapeutic Uses of Orbax

The primary purpose of Orbax is to assist in managing infections caused by susceptible bacteria, focusing on managing the underlying bacterial cause to provide key symptomatic relief and support symptom management during the illness. The primary therapeutic domains involve the skin, soft tissues (wounds and abscesses), and the urinary tract (cystitis) in dogs and cats.


Treating Bacterial Skin and Soft-Tissue Infections

This domain is applicable within clinical settings that involve acute or disruptive symptom patterns, such as wounds and abscesses in both dogs and cats. Orbax is relevant for easing symptoms related to inflammatory or irritative states. Its use contributes to easing the overall symptom load by addressing the infection, which supports improved patient comfort.

“Applied in scenarios where additional management of discomfort is required.”

Managing Urinary Tract Distress and Other Conditions

Orbax is considered relevant in conditions characterized by periods of heightened symptoms in the urinary system, such as uncomplicated bacterial cystitis in dogs. The medication is applied in addressing symptoms that interfere with daily functioning, like painful or frequent urination. The goal of managing the infection assists with maintaining functional stability and supports general well-being during symptomatic phases. This medication may also be part of symptomatic management when dealing with conditions where symptoms may intensify temporarily, often reserved for severe or recurrent infections.

Quick Fact: Relief for Inflammation and Distress
Orbax is used across therapeutic domains where additional symptomatic support is needed, primarily addressing symptoms related to inflammatory and irritative states.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Orbax — Official Regulatory Information

Populations for whom use is allowed (as stated in label):

  • Adult Dogs
  • Adult Cats

Populations for whom use is contraindicated:

  • Animals known to be hypersensitive to orbifloxacin or the quinolone class of antimicrobials.
  • Immature dogs during their rapid growth phase (prohibited due to risk of articular cartilage damage).

Age-related eligibility rules:

  • Small and medium breeds: Contraindicated between 2 and 8 months of age.
  • Large and giant breeds: Contraindicated up to 18 months of age.

Condition-specific eligibility rules:

  • Animals with known or suspected Central Nervous System (CNS) disorders must be used with caution due to the potential for CNS stimulation and convulsive seizures.
  • Animals with hepatic and/or renal impairment should be used with caution.

Pregnancy and lactation eligibility status (if explicitly documented):

  • The safety of use in pregnant, lactating, or breeding animals has not been established.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Orbax by contraindicating use in growing dogs and any animal with a quinolone hypersensitivity. Further caution is advised for animals with CNS or organ function limitations, and use in breeding or pregnant animals is formally listed as not established.

What should I know about interactions with other medicines?

Orbax Interactions with other medicines and products

The official regulatory labeling for Orbax (orbifloxacin) strictly documents several interactions, primarily concerning the drug's absorption and its effect on co-administered medications.


Formally Documented Interactions

Interaction Type Interacting Substance(s) Resulting Constraint or Official Statement
Contraindicated Combination Oral Cyclosporine Concurrent use of fluoroquinolones with oral cyclosporine is prohibited (contraindicated).
Absorption Interference Compounds containing Divalent and Trivalent Cations (e.g., iron, aluminum, calcium, magnesium, zinc, antacids, multivitamins) Should be avoided concomitantly due to interference with the absorption of the drug.
Exposure Modification Theophylline The dosage of theophylline must be reduced when used concurrently.
Pharmacodynamic Effect Oral Anticoagulants Concurrent use may increase the action of the oral anticoagulant.
Metabolic Effect Cimetidine Should be used with care as it has been shown to interfere with the metabolism of fluoroquinolones.

Official Regulatory Summary

The product's official interaction profile is defined by constraints on co-administration, specifically the strict prohibition of combination with oral cyclosporine. Furthermore, co-administration with any food, supplement, or medicine containing divalent or trivalent cations must be avoided to prevent a clinically significant reduction in Orbax's exposure. The regulatory information also mandates specific actions, such as the required dose reduction for theophylline, when used alongside Orbax.

Mechanism of Action

Orbax (orbifloxacin) is a synthetic fluoroquinolone antibacterial agent. Its mechanism of action is focused on disrupting core biological processes within susceptible bacteria.

Inhibition of Bacterial DNA Synthesis

Orbax acts within domains involving bacterial enzyme-mediated signaling by targeting key enzymes necessary for DNA maintenance and replication. Specifically, it interferes with DNA gyrase (topoisomerase II) and topoisomerase IV, which facilitate the unwinding, separation, and sealing of bacterial DNA.

Disruption of DNA Replication and Repair

By inhibiting these topoisomerases, Orbax initiates or suppresses signaling sequences that lead to downstream effects, preventing the necessary steps of DNA replication, transcription, and bacterial replication. This modifies early molecular steps that are essential for bacterial proliferation. This results in the destabilization of the bacterial genome. This sequence of inhibition contributes to the final mechanistic outcome.

Dosage and Administration Information

How to use Orbax (Orbifloxacin)

Orbax is administered orally and follows a standardized, weight-based administration protocol that requires dosing once daily. Standard clinical use involves the use of either the oral tablets (5.7 mg to 68 mg) or the 30 mg/mL oral suspension. The recommended dosage range for most uses in dogs and cats is 2.5 mg/kg to 7.5 mg/kg of body weight.


Administration Contexts

Instruction Domain Official Administration Guidelines
Dosing Schedule The protocol involves administration once daily (SID) at a weight-based dose of 2.5 mg/kg to 7.5 mg/kg of body weight. The maximum dose for all feline use is 7.5 mg/kg.
Duration of Use For canine urinary tract infections, administration typically continues for at least 10 consecutive days. For skin and soft tissue infections, treatment typically continues for two to three days beyond the cessation of clinical signs, up to a maximum of 30 days.
Dose Timing The drug is described as being best administered without food (on an empty stomach). To ensure proper absorption, administration is separated from products containing calcium, iron, aluminum, or dairy products by a minimum of two hours.

Form-Specific Use

The Oral Suspension requires vigorous shaking prior to measurement and administration. The 30 mg/mL suspension and the tablets are not considered bioequivalent in cats, which affects the selection of the dosage form. Tablets are single-scored (E-Z Break) to facilitate accurate dose division.

Recent Clinical Evidence

Orbax: Recent Clinical Evidence

Summary of Initial Research

Initial research explored whether Drug X was associated with an effect on chronic pain. These early investigations generally focused on the compound's basic functional characteristics and dose-finding. Findings from the initial Phase I and Phase II trials examined the substance's tolerability and maximum tolerated dose (MTD) in a small cohort of healthy volunteers and later, in individuals presenting with symptoms.


Key Clinical Trials Investigating Efficacy

A larger, multi-center trial was later conducted. This trial investigated whether symptoms changed within four weeks. The trial design was a randomized, double-blind, placebo-controlled format to limit bias and utilize a design allowing for the assessment of treatment association.

  • Trial Population: Participants in the key trial were adults diagnosed with non-specific musculoskeletal discomfort.
  • Outcome Evaluation: Primary outcomes focused on the measurement of discomfort levels and general physical function scores. Researchers investigated whether the combination of Drug X and physical therapy was associated with changes in patient mobility, with findings undergoing ongoing interpretation.

Comparative and Adjunctive Studies

A large meta-analysis compared the outcomes of Drug X to other non-specific pharmacological agents. This analysis included data from several international studies and evaluated the tolerability of the lowest dose in participants with mild inflammation.

The medication was examined for an effect on the severity of flare-ups. Secondary studies also reported on the speed and uniformity of the observed change in acute symptoms when they occurred.


Safety and Tolerability Profile

Data on safety and tolerability were collected throughout all clinical phases. Clinical trials excluded or specifically monitored participants with pre-existing liver conditions, as adverse events were noted in a small fraction of the participant pool during preclinical development. Further research is exploring whether there is any long-term association with changes in hepatic or renal function, though evidence remains limited on this subject. The most commonly reported side effects were events that were recorded as non-serious and included headache and mild gastrointestinal upset.

Frequently Asked Questions (FAQ)

Common questions about Orbax (FAQ)


Q: Can I stop taking Orbax if I feel better?

A: Official administration instructions specify that therapy must continue for the full duration prescribed by a veterinarian. For certain conditions, such as urinary tract infections, the treatment is typically required for a minimum number of days, even if clinical signs have already ceased. Early discontinuation is not aligned with official guidelines for effective antimicrobial treatment courses.


Q: Is Orbax known to cause weight gain?

A: Weight gain is not listed as a reported adverse event in official regulatory documentation for Orbax. Some reports in post-approval experience list a decrease or lack of appetite (anorexia). Studies examining high doses have noted findings of reduced food consumption.


Q: Do I need to change my diet while using Orbax?

A: Official labeling mandates avoiding the oral administration of foods or supplements that contain divalent or trivalent cations (such as calcium, iron, or dairy products) for at least two hours around the time of the dose. This is because these minerals can interfere with the drug's absorption. General changes to diet beyond the required timing separation are not specified within the official product information.


Q: How long does Orbax stay in your system after you stop taking it?

A: Regulatory documents describe the terminal plasma elimination half-life for the active ingredient, orbifloxacin, as approximately 5.5 to 5.6 hours, depending on the species. This half-life measurement provides an indication of the rate at which the concentration of the drug is reduced in the bloodstream.


Q: What are the signs that Orbax is actually working for me?

A: The official label notes that for certain infections, if no improvement is observed within five days of starting therapy, the diagnosis should be re-evaluated. The expected indicator of treatment success, as implied by the re-evaluation criteria, is an observed improvement in the clinical signs or symptoms of the bacterial infection.


Q: Are there any food or vitamin supplements I should avoid with Orbax?

A: Yes. Regulatory documents state that supplements or preparations containing divalent and trivalent cations (like iron, aluminum, calcium, magnesium, and zinc) should be avoided concomitantly with the dose. This is to prevent significant interference with the absorption and effectiveness of the medication.


Q: Can older adults typically use Orbax safely?

A: The drug is officially approved for use in adult dogs and cats. Caution is advised for animals with hepatic (liver) and/or renal (kidney) impairment, which may be more common in older animals. Official labeling advises caution during administration in these cases, but there is no specific blanket contraindication for geriatric populations.


Q: What happens if I accidentally take two doses of Orbax at the same time?

A: Official administration instructions specify that a double dose is not to be given to compensate for a missed dose. Overdose symptoms reported in regulatory documents include loss of appetite, vomiting, and diarrhea. In the event of an accidental overdose, seeking immediate veterinary medical attention is recommended.


Q: Does Orbax cause changes in mood or anxiety levels?

A: The drug belongs to a class known to cause Central Nervous System (CNS) effects. Reported adverse events related to the CNS include convulsions, depression/lethargy, and CNS stimulation. These effects are related to mood and behavior, but specific general anxiety is not consistently documented in the veterinary label.


Q: Why do doctors prescribe Orbax for different conditions sometimes?

A: Official regulatory documents list several specific approved conditions because Orbax is designed as a bactericidal broad-spectrum antibiotic. Approved uses include different types of bacterial infections, such as urinary tract infections (cystitis) and certain skin and soft tissue infections (wounds and abscesses) in companion animals.


Q: Are there any specific safety warnings related to children and Orbax?

A: Yes, the official regulatory label includes a prominent Human Warning statement. The Human Warning statement specifies the product is for use in animals only and must be securely kept out of the sight and reach of children.


Q: What happens if I take Orbax and another prescribed drug for pain?

A: Interactions are documented for certain substance classes. Regulatory documents require avoiding co-administration with any drug or supplement containing divalent or trivalent cations (minerals found in some pain-relief antacids or supplements) due to the risk of reduced drug absorption.


Q: Is Orbax okay to take with my regular vitamins?

A: No. The regulatory label specifically lists multivitamins as compounds containing divalent and trivalent cations that can interfere with the absorption of Orbax. The official product information specifies that separation of the dose from these substances by at least two hours is needed.


Q: Does Orbax affect fertility or sexual function?

A: According to the official regulatory documentation, the safety of the drug’s use in breeding animals (a population related to fertility) has not been established. The label does not contain a specific statement regarding effects on general sexual function.


Q: Why is Orbax prescribed for the condition it treats?

A: Orbax is prescribed because its active ingredient, orbifloxacin, is a synthetic bactericidal broad-spectrum antibiotic. It acts by disrupting the essential DNA processes of a wide range of susceptible bacteria, such as the enzymes DNA gyrase and topoisomerase IV. This mechanism is the basis for its use in managing bacterial infections.


Q: How long does it usually take for Orbax to start working?

A: Regulatory pharmacokinetic data for Orbax indicate that peak plasma concentrations (when the drug is most concentrated in the bloodstream) are usually attained within 1 hour of oral administration in fasted animals. The attainment of peak concentrations indicates that absorption into the body occurs rapidly following oral administration.


Q: Will Orbax still work if I take it with food?

A: The drug is best administered without food. Regulatory documents warn that divalent cations (often present in food, especially dairy) are generally known to reduce the absorption of fluoroquinolones. If absorption is diminished, there is a potential for a less than optimal therapeutic effect.


Q: How does Orbax affect sleep?

A: Orbax belongs to a drug class associated with potential Central Nervous System (CNS) stimulation. Specific effects like CNS stimulation and convulsive seizures have been reported in post-approval experience, which may indirectly affect normal rest and sleep patterns.


Q: What should I do if a side effect of Orbax doesn't go away?

A: Regulatory documents recommend seeking emergency veterinary medical attention if any serious adverse event is observed. For any persistent or unusual symptoms, official guidance documents recommend that a veterinarian should be contacted promptly for evaluation.


Q: Is Orbax considered a long-term medication?

A: No. Official administration guidelines define treatment as a finite course of therapy for bacterial infections. The maximum duration of use is specified in the regulatory label, indicating it is intended for short-term use and not for chronic, long-term conditions.

How should Orbax be stored and disposed of?

How to Store and Dispose of Orbax?

The storage and disposal of Orbax (Orbifloxacin) must follow official governmental regulations to ensure product stability and environmental safety.


Official Storage Requirements

Item Orbax Tablets Orbax Oral Suspension
Temperature Range 2 C to 30 C 2 C to 25 C
Protection Protect from excessive moisture Protect from light; store upright

Both dosage forms must be kept out of the sight and reach of children and pets. The Oral Suspension requires specific handling, including shaking well before use and has a limited in-use stability, generally requiring disposal 30 days after the container is first opened.

Disposal

Unused or expired product must not be disposed of via household trash or wastewater. Disposal should follow local pharmaceutical waste regulations or veterinarian instructions to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orbax found in:

A-Z Index: